Non-ossifying fibromas (NOFs) are benign bone tumors that can affect bone development in children and adolescents. They are the most common type of bone tumor in this age group, accounting for up to 15% of all bone tumors. NOFs are usually asymptomatic, but they can cause pain and deformity if they grow in close proximity to a joint or if they compress a nerve. The exact cause of NOFs is not known, but they are believed to be related to abnormal bone growth. In this article, we will explore the impact of NOFs on bone development and how they can be managed.
NOFs are benign tumors of the bone that typically occur in the long bones of the arms and legs, but can also occur in other bones such as the ribs, pelvis, and spine. They are most common in children and adolescents, especially those between the ages of 5 and 15. NOFs are made up of spindle-shaped cells that are surrounded by a fibrous capsule. They are often referred to as �fibrous cortical defects� because they form in the outer layer of the bone (the cortex).
The exact cause of NOFs is not known, but it is believed to be related to abnormal bone growth. It is thought that the tumor cells form as a result of an imbalance between bone formation and bone resorption. This imbalance can be caused by genetic factors, environmental factors, or a combination of both.
NOFs are usually asymptomatic, but they can cause pain and deformity if they grow in close proximity to a joint or if they compress a nerve. Symptoms may include pain, swelling, and tenderness in the affected area. In some cases, the tumor may be visible on X-rays.
The diagnosis of NOFs is usually made based on the patient�s symptoms and imaging studies such as X-rays or CT scans. A biopsy may also be performed to confirm the diagnosis.
NOFs are usually treated with observation and monitoring, as most tumors will not grow or cause any symptoms. Surgery may be necessary if the tumor is causing pain or deformity, or if it is growing rapidly. Surgery is usually done to remove the tumor and any affected bone. In some cases, radiation therapy may also be used.
NOFs can affect bone development in children and adolescents. The tumors can cause deformity and pain, and they can interfere with the normal growth of the bone. In some cases, the tumor can cause the bone to become thicker or weaker, which can lead to long-term problems with the development of the bone.
Non-ossifying fibromas (NOFs) are the most common type of bone tumor in children and adolescents. They are usually asymptomatic, but can cause pain and deformity if they grow in close proximity to a joint or if they compress a nerve. The exact cause of NOFs is not known, but it is believed to be related to abnormal bone growth. NOFs can affect bone development in children and adolescents, and can cause deformity and pain. Treatment usually involves observation and monitoring, but surgery may be necessary if the tumor is causing pain or deformity, or if it is growing rapidly.
1.
Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.
2.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
3.
New First-Line Option for Advanced ALK-Positive Lung Cancer
4.
Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.
5.
Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
3.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
4.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
5.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation